Fexaramine (BioDeep_00000010812)
代谢物信息卡片
化学式: C32H36N2O3 (496.2725786)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN(C)C1=CC=C(C=C1)C2=CC=C(C=C2)CN(C3=CC=CC(=C3)C=CC(=O)OC)C(=O)C4CCCCC4
InChI: InChI=1S/C32H36N2O3/c1-33(2)29-19-17-27(18-20-29)26-15-12-25(13-16-26)23-34(32(36)28-9-5-4-6-10-28)30-11-7-8-24(22-30)14-21-31(35)37-3/h7-8,11-22,28H,4-6,9-10,23H2,1-3H3/b21-14+
数据库引用编号
13 个数据库交叉引用编号
- ChEBI: CHEBI:80003
- KEGG: C15649
- PubChem: 5326713
- PubChem: 447713
- Metlin: METLIN70998
- DrugBank: DB02545
- ChEMBL: CHEMBL192966
- CAS: 2197131-49-8
- CAS: 574013-66-4
- PMhub: MS000024708
- PubChem: 17396639
- NIKKAJI: J2.795.664E
- KNApSAcK: 80003
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Wanqiu Huang, Zhijun Cao, Wenxin Wang, Zhongcheng Yang, Shixuan Jiao, Ya Chen, Siliang Chen, Luyong Zhang, Zheng Li. Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease.
Bioorganic chemistry.
2024 Feb; 143(?):107071. doi:
10.1016/j.bioorg.2023.107071. [PMID: 38199141] - Yiming Yin, Mengge Wang, Wenjie Gu, Lili Chen. Intestine-specific FXR agonists as potential therapeutic agents for colorectal cancer.
Biochemical pharmacology.
2021 04; 186(?):114430. doi:
10.1016/j.bcp.2021.114430. [PMID: 33556338] - Yujie Liu, An Song, Xi Yang, Yunfeng Zhen, Weiwei Chen, Linquan Yang, Chao Wang, Huijuan Ma. Farnesoid X receptor agonist decreases lipid accumulation by promoting hepatic fatty acid oxidation in db/db mice.
International journal of molecular medicine.
2018 Sep; 42(3):1723-1731. doi:
10.3892/ijmm.2018.3715. [PMID: 29901078] - C Daniel De Magalhaes Filho, Michael Downes, Ronald M Evans. Farnesoid X Receptor an Emerging Target to Combat Obesity.
Digestive diseases (Basel, Switzerland).
2017; 35(3):185-190. doi:
10.1159/000450909. [PMID: 28249279] - Shi-Ying Cai, Liangshi Xiong, Charles G Wray, Nazzareno Ballatori, James L Boyer. The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution.
American journal of physiology. Regulatory, integrative and comparative physiology.
2007 Sep; 293(3):R1400-9. doi:
10.1152/ajpregu.00781.2006. [PMID: 17567710] - Thierry Claudel, Ekkehard Sturm, Folkert Kuipers, Bart Staels. The farnesoid X receptor: a novel drug target?.
Expert opinion on investigational drugs.
2004 Sep; 13(9):1135-48. doi:
10.1517/13543784.13.9.1135. [PMID: 15330745] - Michael Downes, Mark A Verdecia, A J Roecker, Robert Hughes, John B Hogenesch, Heidi R Kast-Woelbern, Marianne E Bowman, Jean-Luc Ferrer, Andrew M Anisfeld, Peter A Edwards, John M Rosenfeld, Jacqueline G A Alvarez, Joseph P Noel, K C Nicolaou, Ronald M Evans. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR.
Molecular cell.
2003 Apr; 11(4):1079-92. doi:
10.1016/s1097-2765(03)00104-7. [PMID: 12718892] - B K Tang, T Inaba, W Kalow. N-hydroxyamobarbital: the second major metabolite of amobarbital in man.
Drug metabolism and disposition: the biological fate of chemicals.
1975 Nov; 3(6):479-86. doi:
NULL. [PMID: 1222]